BioSignal Analytics is organized around improving the quality of healthcare through the use of automated interpretation technology based on state of the art machine learning algorithms. The firm leverages big data resources to train sophisticated models capable of self-organizing unstructured data and discovering underlying structure. Biosignal's initial product, AutoEEG, leverages validated deep learning techniques and the worlds largest EEG corpus to achieve unprecedented performance in automated EEG analysis. Initial applications include real-time seizure detection for long-term monitoring studies in epilepsy monitoring units and intensive care units to improve patient outcomes and increase access to care. BioSignal Analytics is a portfolio company of Phase 1 Ventures.
